Pharmacist-Led telehealth aims to tame gout flares in veterans

NCT ID NCT06887452

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether having a pharmacist guide gout medication adjustments through regular telehealth visits can improve outcomes compared to usual care. It will enroll 310 veterans at five VA medical centers and follow them for up to two years. The goal is to lower uric acid levels and reduce painful gout flares.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
allopurinol or febuxostat
What this could lead to
If successful, this could show that pharmacist-led telehealth helps more people with gout reach their uric acid goals and have fewer flares.
What could go wrong
This is a relatively small study (310 people) and compares two management approaches, not a new drug. Results may not apply to all gout patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arthritis, Gouty gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Philadelphia, Pennsylvania, 19104-4551, United States

  • Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE

    Omaha, Nebraska, 68105-1850, United States

  • VA Portland Health Care System, Portland, OR

    Portland, Oregon, 97207-2964, United States

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    Seattle, Washington, 98108-1532, United States

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah, 84148-0001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.